Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Korea Institute Of Oriental Medicine manages 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 2 distinct art units and 2 distinct examiners. INAM, SAHAR is the busiest examiner for the company, with 1 pending office action. This distribution indicates that each pending matter is being reviewed by a different examiner in a different art unit.
The involvement of 2 distinct examiners for 2 pending office actions means that prosecution outcomes are independent of any single examiner's tendencies. Furthermore, the 2 distinct art units involved indicate that the company's biotechnology innovations span multiple technical classifications. Practitioners must be prepared to navigate the specific requirements of these 2 distinct art units. This decentralized structure requires a versatile strategy to address the specific requirements of each examiner and art unit.
With 2 pending office actions, the portfolio is active but manageable. The strategy appears to favor a broad approach, engaging with 2 distinct examiners to secure intellectual property rights. Because no single examiner handles more than 1 pending office action, the company must maintain consistent arguments across the 2 distinct art units to ensure a unified patent portfolio in the Biotechnology & Pharmaceuticals sector. Success depends on navigating the diverse expectations of 2 different individuals.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SPAINE, ROBERT FRANKLIN | 1 | 75.0% | +0.0% |
| INAM, SAHAR | 1 | 100.0% | +0.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18722979 | COMPOSITION FOR PREVENTING, AMELIORATING OR TREATING RESPIRATORY DISEASE COMPRISING LYSIMACHIA MAURITIANA EXTRACT AS EFFECTIVE COMPONENT | SPAINE, ROBERT FRANKLIN | — |
| 18723290 | USE OF ARISTOLOXAZINE C HAVING ANTICANCER ACTIVITY | INAM, SAHAR | — |
| Art Unit | Apps |
|---|---|
| 1655 | 1 |
| 1622 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18722979 | COMPOSITION FOR PREVENTING, AMELIORATING OR TREATING RESPIRATORY DISEASE COMPRISING LYSIMACHIA MAURITIANA EXTRACT AS EFFECTIVE COMPONENT | SPAINE, ROBERT FRANKLIN | 1655 | §103§112 | Non-Final OA | — | Pending | Jun 21, 2024 |
| 18723290 | USE OF ARISTOLOXAZINE C HAVING ANTICANCER ACTIVITY | INAM, SAHAR | 1622 | §103§112 | Non-Final OA | — | Pending | Jun 21, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialKorea Institute Of Oriental Medicine has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Robert Franklin Spaine has the most, with 1 of Korea Institute Of Oriental Medicine's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
